http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0018763-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_40a92325286ca98dbffa06d2c67ed064
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b5c01ebe8922232ff11831d99633a8c7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5725e21841e5ee5896b951ccb7e93bcd
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-04
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-14
filingDate 1999-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_763f1151bfa183aff3abdae2b41607eb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd118b255b41c94e0bb81f43ba6c04e8
publicationDate 2000-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-0018763-A3
titleOfInvention 2-(2,3-dihydrobenzofuran-5-yl)-4-aminomethylimidazoles: dopamine receptor subtype specific ligands
abstract Disclosed are compounds of formula (I): or the pharmaceutically acceptable acid addition salts thereof wherein: n is an integer; R1 represents an organic or inorganic group; R2 represents halogen or C1-C6 alkyl; RN is an alkylene carrying a substituted piperazine, piperidine, or tetrahydropyridine; and R4 is hydrogen or C1-C6 alkyl, which compounds are useful for the treatment and/or prevention of neuropsychological disorders including, but not limited to, schizophrenia, mania, dementia, depression, anxiety, compulsive behavior, substance abuse, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agent (blockade/modulation of dopamine receptors).
priorityDate 1998-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9610018-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9616040-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9212134-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-2061515-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9743279-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9616057-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID70245568
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID233532370
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID681
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399686

Total number of triples: 26.